Advertisement

Topics

Samsung Bioepis First to Obtain European Commission Approval for a Third Anti-TNF-α Biosimilar with Imraldi® (adalimumab)

19:00 EDT 24 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Imraldi®, a biosimilar referencing Humira® 1 (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial ...

Other Sources for this Article

Samsung Bioepis Co., Ltd.
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com

NEXT ARTICLE

More From BioPortfolio on "Samsung Bioepis First to Obtain European Commission Approval for a Third Anti-TNF-α Biosimilar with Imraldi® (adalimumab)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...